Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Brain and Leptomeningeal Metastases Responding to Intrathecal Treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain, leptomeninges

More than 5 years after her September 2019 diagnosis, neurological symptoms had resolved, cerebrospinal fluid remained negative for tumor cells, and maintenance treatment was continuing in February 2025.

PubMed CentralRead more →

Early-stage mixed breast carcinoma found during LGI1 limbic encephalitis workup

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER 95-100% positive; PR 80% positive; HER2-negative

She gradually recovered after immunotherapy for limbic encephalitis and excision of the early-stage breast tumor, and had returned to part-time work 12 months after discharge.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →

Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer With Severe Myelitis During Pembrolizumab Treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative, PR-negative, HER2-negative, germline PALB2 variation

Imaging showed a complete tumor response before surgery, and surgery 6 months later found no residual breast cancer or involved sentinel nodes.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Maggie's Survivor Story

Patient Info: Maggie, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lungs, lymph nodes; possible liver

Diagnosed in 2022 with de novo Stage IV triple-negative breast cancer involving the lungs and lymph nodes, with possible liver involvement. After entering a chemotherapy/immunotherapy clinical trial, she reported being cancer-free / no evidence of disease for well over 1 year as of February 2025.

The Patient StoryRead more →

Stage IIIC triple-negative breast cancer with pembrolizumab-related HLH/DIC and pathologic complete response

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative/HR-negative breast cancer with germline BRCA1 pathogenic mutation. HLH/DIC episode had high IL-6

Surgery confirmed ypT0ypN0 pathologic complete response after neoadjuvant carboplatin, paclitaxel, and pembrolizumab, and she remained recurrence-free while being monitored without additional cancer-directed treatment.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Juliette's Survivor Story

Patient Info: Juliette Landgrave, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

After egg preservation, 16 rounds of chemotherapy with complete response, lumpectomy, 25 radiation sessions and 1 year of immunotherapy, Juliette was cancer-free as of December 2024.

City of HopeRead more →

Stage II Triple-Negative Breast Cancer: Italia's Survivor Story

Patient Info: Italia Russell, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA mutation

As of October 2024, Italia had no evidence of disease after Stage II triple-negative breast cancer responded to chemotherapy, the tumor was gone by double mastectomy, and she was completing immunotherapy with 3 infusions left.

Cleveland ClinicRead more →

Triple-negative breast cancer in remission after chemotherapy and pembrolizumab

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative

Triple-negative breast cancer was in remission, with PET-CT showing no new primary or secondary tumors, while pembrolizumab-related adrenal insufficiency required ongoing endocrine management.

PubMed CentralRead more →

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed CentralRead more →

Stage II Breast Cancer Treatment Complicated by Scleroderma-Like Skin Changes

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER low-positive; PR-negative; HER2-negative

Her cancer remained stable during combination treatment. After morphea-like skin changes developed during therapy, treatment was modified and the skin condition improved 6 months after docetaxel was stopped.

PubMed CentralRead more →

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed CentralRead more →

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed CentralRead more →

Exercise Trainer Helps Detect Brain Metastases in a Woman With Long-Standing Metastatic Breast Cancer

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: liver, bones, lymph nodes, kidney, brain

She died 5 months after the brain metastases were diagnosed, roughly 7 years after her original 2014 breast-cancer diagnosis.

PubMed CentralRead more →

Stage IV Breast Cancer: Brittney's Patient Story

Patient Info: Brittney Beadle, Female, Under 40 | Stage IV

Metastatic Site: Bones; liver; brain; lungs

As of August 2023, Brittney was living with Stage IV breast cancer on ENHERTU every 21 days, with brain clear for 4.5 years, liver clear, and bone and lung disease regressing.

The Patient StoryRead more →

Stage II Breast Cancer: Annie's Patient Story

Patient Info: Annie, Female, 40s | Stage II

As of 2023, Annie was still receiving care for Stage II breast cancer after completing chemotherapy and hormonal therapy, with lumpectomy, lymphadenectomy, radiation therapy, and immunotherapy still ahead in her plan.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Grace's Patient Story

Patient Info: Grace, Female, 60s | Stage II

Grace was still in treatment for Stage II breast cancer, including lumpectomy-based care, chemotherapy, radiation therapy, and immunotherapy, and reported that treatment was working despite difficult side effects and job loss.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Joanna's Survivor Story

Patient Info: Joanna, Female, Under 40 | Stage III

By late 2023, Joanna had completed treatment for Stage III breast cancer, was no longer taking medication, and described herself as living free of cancer.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Margaret's Patient Story

Patient Info: Margaret | Stage III

Margaret remained hopeful while managing severe treatment effects, sepsis, financial pressure, and reduced time with her children.

Our Cancer StoriesRead more →